Search results for "Lymphatic"

showing 10 items of 1179 documents

Pharmacogenomics and the treatment of acute myeloid leukemia.

2016

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability. Several pharmacogenetic studies have analyzed the impact of polymorphisms in genes encoding transporters, metabolizers or molecular targets of chemotherapy agents. A systematic review on all eligible studies was carried out in order to estimate the effect of polymorphisms of anthracyclines and cytarabine pathways on efficacy and toxicity of AML treatment. Other emerging gene…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBiologyMalignancy03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsmedicineSNPHumansGenetic variabilityPharmacologyChemotherapyPolymorphism GeneticMyeloid leukemiamedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyPharmacogenetics030220 oncology & carcinogenesisPharmacogenomicsImmunologyCytarabineMolecular MedicinePharmacogeneticsmedicine.drugPharmacogenomics
researchProduct

TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer

2015

ABSTRACT In experimental mouse models of cancer, increasingly compelling evidence point toward a contribution of tumor associated macrophages (TAM) to tumor lymphangiogenesis. Corresponding experimental observations in human cancer remain scarce although lymphatic metastasis is widely recognized as a predominant route for tumor spread. We previously showed that, in malignant tumors of untreated breast cancer (BC) patients, TIE-2-expressing monocytes (TEM) are highly proangiogenic immunosuppressive cells and that TIE-2 and VEGFR signaling pathways drive TEM immunosuppressive function. We report here that, in human BC, TEM express the canonical lymphatic markers LYVE-1, Podoplanin, VEGFR-3 an…

0301 basic medicinePathologymedicine.medical_specialtyAngiogenesisTIE-2-expressing monocytesImmunologyBiology03 medical and health sciences0302 clinical medicineBreast cancerbreast cancermedicineImmunology and Allergytumor microenvironmentOriginal ResearchTumor microenvironmentKinaseCancermedicine.disease3. Good healthLymphangiogenesisTIE-2expressing monocytes030104 developmental biologyLymphatic systemOncologyPodoplaninlymphaticsAngiogenesis030215 immunology
researchProduct

Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

2016

AbstractTreatment of high-risk childhood neuroblastoma is a clinical challenge which has been hampered by a lack of reliable neuroblastoma mouse models for preclinical drug testing. We have previously established invasive and metastasising patient-derived orthotopic xenografts (PDXs) from high-risk neuroblastomas that retained the genotypes and phenotypes of patient tumours. Given the important role of the tumour microenvironment in tumour progression, metastasis, and treatment responses, here we analysed the tumour microenvironment of five neuroblastoma PDXs in detail. The PDXs resembled their parent tumours and retained important stromal hallmarks of aggressive lesions including rich bloo…

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchStromal cellGenotypeTumour stromaBiologyPolymorphism Single NucleotideMetastasisMetastasisPaediatric cancer03 medical and health sciencesMiceNeuroblastoma0302 clinical medicineNeuroblastomamedicineTumor MicroenvironmentAnimalsHumansPatient-derived xenograft (PDX)Tumor microenvironmentTumour microenvironmentNeovascularization Pathologicmedicine.diseaseXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologyLymphatic systemOncology030220 oncology & carcinogenesisCancer-Associated FibroblastsImmunohistochemistryBlood VesselsChildhood NeuroblastomaCancer letters
researchProduct

Plasmablastic lymphoma as a manifestation of the human immunodeficiency virus: Case report

2020

Plasmablastic lymphoma is a rare subtype of non-Hodgkin’s lymphoma, which generally presents an aggressive clinical course and low survival rates. It is strongly associated with HIV infection and the most common site of involvement of the territory of the head and neck is Waldeyer’s lymphatic ring, followed by the gastrointestinal tract, lymph nodes and skin. The morphological characteristics of PBL in the oral cavity / jaw in the context of HIV infection show diffuse sheets of large immunoblastic cells with abundant cytoplasm, vesicular chromatin and prominent nucleus, a small located in the center with plasma cells differentiation. The main goal of this article is to review the literature…

0301 basic medicinePathologymedicine.medical_specialtyHuman immunodeficiency virus (HIV)Case ReportContext (language use)medicine.disease_cause03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)immune system diseaseshemic and lymphatic diseasesmedicineGeneral DentistryGastrointestinal tractOral Medicine and Pathologybusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseLymphoma030104 developmental biologyLymphatic system030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASLymphbusinessPlasmablastic lymphomaJournal of Clinical and Experimental Dentistry
researchProduct

Lymphatic Endothelial Cells Control Initiation of Lymph Node Organogenesis

2017

Lymph nodes (LNs) are strategically situated throughout the body at junctures of the blood vascular and lymphatic systems to direct immune responses against antigens draining from peripheral tissues. The current paradigm describes LN development as a programmed process that is governed through the interaction between mesenchymal lymphoid tissue organizer (LTo) cells and hematopoietic lymphoid tissue inducer (LTi) cells. Using cell-type-specific ablation of key molecules involved in lymphoid organogenesis, we found that initiation of LN development is dependent on LTi-cell-mediated activation of lymphatic endothelial cells (LECs) and that engagement of mesenchymal stromal cells is a succeedi…

0301 basic medicinePathologymedicine.medical_specialtygovernment.form_of_governmentOrganogenesis[SDV]Life Sciences [q-bio]Immunology610 Medicine & healthMice TransgenicBiologyChoristoma10263 Institute of Experimental Immunology03 medical and health sciencesMiceImmune systemLymphotoxin beta ReceptormedicineLymph node stromal cellImmunology and AllergyAnimalsLymph nodeCells CulturedComputingMilieux_MISCELLANEOUS2403 ImmunologyReceptor Activator of Nuclear Factor-kappa BMesenchymal stem cellNF-kappa BEndothelial CellsCell DifferentiationMesenchymal Stem Cells2725 Infectious DiseasesEmbryo MammalianCell biologyMice Inbred C57BLHaematopoiesisLymphatic EndotheliumReceptors Lysosphingolipid030104 developmental biologyInfectious Diseasesmedicine.anatomical_structureLymphatic system2723 Immunology and Allergygovernment570 Life sciences; biology[SDV.IMM]Life Sciences [q-bio]/ImmunologyLymphLymph NodesSignal Transduction
researchProduct

Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma

2017

Background Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is specifically expressed in lymphatic endothelial cells. Studies have shown that assessment of podoplanin expression in the epithelial cells can be used to predict the malignant transformation of potentially malignant disorders and the metastatic tendency of primary head and neck squamous cell carcinoma. The aim of our study was to compare the expression of podoplanin in oral leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma with that in normal buccal mucosa by immunohistochemical methods. Material and methods Immunohistochemical expression of podoplanin was analyzed in 20 cases each of or…

0301 basic medicinePathologymedicine.medical_specialtymedicine.drug_classgovernment.form_of_governmentMonoclonal antibodyMalignant transformation03 medical and health sciences0302 clinical medicineDownregulation and upregulationmedicineGeneral DentistryOral Medicine and Pathologybusiness.industryResearchmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Head and neck squamous-cell carcinomaLymphatic Endotheliumstomatognathic diseases030104 developmental biologyOral submucous fibrosisPodoplanin030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASgovernmentImmunohistochemistrybusiness
researchProduct

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expressio…

2019

Aberrant activation of the JAK/STAT pathway is thought to be the critical event in the pathogenesis of the chronic myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia and primary myelofibrosis. The most frequent genetic alteration in these pathologies is the activating JAK2V617F mutation, and expression of the mutant gene in mouse models was shown to cause a phenotype resembling the human diseases. Given the body of genetic evidence, it has come as a sobering finding that JAK inhibitor therapy only modestly suppresses the JAK2V617F allele burden, despite showing clear benefits in terms of reducing splenomegaly and constitutional symptoms in patients. To gain a better …

0301 basic medicinePhysiologyClone (cell biology)Mice0302 clinical medicineAnimal CellsBone MarrowImmune PhysiologyMedicine and Health SciencesBlood and Lymphatic System ProceduresTransgenesBone Marrow TransplantationRegulation of gene expressionMultidisciplinaryQRAnimal ModelsBody FluidsPhenotypesBloodExperimental Organism Systems030220 oncology & carcinogenesisMedicineAnatomyCellular TypesResearch ArticleGenetically modified mousePlateletsTransgeneScienceImmunologyMutation MissenseMice TransgenicMouse ModelsSurgical and Invasive Medical ProceduresBone Marrow CellsBiologyResearch and Analysis Methods03 medical and health sciencesModel OrganismsmedicineGeneticsAnimalsHumansAlleleProgenitor cellMyelofibrosisMolecular Biology TechniquesMolecular BiologyTransplantationMyeloproliferative DisordersBlood CellsEssential thrombocythemiaBiology and Life SciencesCell BiologyJanus Kinase 2medicine.diseaseHematopoietic Stem CellsDisease Models Animal030104 developmental biologyAmino Acid SubstitutionGene Expression RegulationImmune SystemCancer researchAnimal StudiesSpleenCloningPLoS ONE
researchProduct

Viral Bcl2s' transmembrane domain interact with host Bcl2 proteins to control cellular apoptosis

2020

© The Author(s) 2020.

0301 basic medicineProgrammed cell deathScienceProtein domainGeneral Physics and AstronomyApoptosisBiologyVirus-host interactionsArticleGeneral Biochemistry Genetics and Molecular BiologyFluorescenceCell Line03 medical and health sciences0302 clinical medicineProtein Domainsimmune system diseaseshemic and lymphatic diseasesmedicineHumansAmino Acid SequenceAuthor CorrectionPeptide sequenceneoplasmsMultidisciplinaryVirus–host interactionsQCell MembraneGeneral ChemistryViral proteinsmedicine.diseaseControl cellLymphomaCell biologyVirusTransmembrane domain030104 developmental biologyProto-Oncogene Proteins c-bcl-2Cell cultureApoptosisDoxorubicin030220 oncology & carcinogenesisbiological phenomena cell phenomena and immunityProtein MultimerizationHydrophobic and Hydrophilic InteractionsProteïnesProtein Binding
researchProduct

Mcl-1 and Bok transmembrane domains : Unexpected players in the modulation of apoptosis

2020

The Bcl-2 protein family comprises both proand antiapoptotic members that control the permeabilization of the mitochondrial outer membrane, a crucial step in the modulation of apoptosis. Recent research has demonstrated that the carboxyl-terminal transmembrane domain (TMD) of some Bcl-2 protein family mem-bers can modulate apoptosis; however, the transmembrane interactome of the antiapoptotic protein Mcl-1 remains largely unexplored. Here, we demonstrate that the Mcl-1 TMD forms homooligomers in the mitochondrial membrane, competes with full-length Mcl-1 protein with regards to its antiapoptotic function, and induces cell death in a Bok-dependent manner. While the Bok TMD oligomers locate p…

0301 basic medicineProtein familyMitochondrionBCL-X(L)Endoplasmic ReticulumInteractome114 Physical sciences03 medical and health sciencesBok0302 clinical medicineProtein DomainsMITOCHONDRIAhemic and lymphatic diseasesAnimalsHumansBcl-2Inner mitochondrial membraneMultidisciplinaryCell DeathChemistryEndoplasmic reticulumapoptosisMcl-1PATHWAYSLOCALIZATIONBiological SciencesTransmembrane protein3. Good healthCell biologytransmembraneTransmembrane domainstomatognathic diseasesGLYCOPHORIN-A DIMERIZATION030104 developmental biologyHELIX PACKINGProto-Oncogene Proteins c-bcl-2BAX030220 oncology & carcinogenesisMitochondrial MembranesPROSURVIVAL BCL-2 PROTEINSMOTIFSURVIVALMyeloid Cell Leukemia Sequence 1 Protein1182 Biochemistry cell and molecular biologyBacterial outer membraneHeLa Cells
researchProduct

SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of m…

2018

Background Chronic myelogenous leukemia (CML) is a myeloproliferative disorder caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, resulting from the t(9;22) chromosomal translocation. Imatinib (gleevec, STI-571) is a selective inhibitor of BCR-ABL activity highly effective in the treatment of CML. However, even though almost all CML patients respond to treatment with imatinib or third generation inhibitors, these drugs are not curative and need to be taken indefinitely or until patients become resistant. Therefore, to get a definitive eradication of leukemic cells, it is necessary to find novel therapeutic combinations, for achieving greater efficacy and fewer side effec…

0301 basic medicineProteomicsCancer ResearchCurcuminCML cellsCellReceptors Cytoplasmic and NuclearKaryopherinsTransfectionlcsh:RC254-282Mass SpectrometrymiR-22/IPO7/HIF-1α axis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemiR-22/IPO7/HIF-1α axiSettore BIO/13 - Biologia Applicatahemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansCML cells; Curcumin; miR-22/IPO7/HIF-1α axis; SWATH-MS; Oncology; Cancer ResearchOncogeneChemistryResearchCML cellImatinibTransfectionmedicine.diseaseHypoxia-Inducible Factor 1 alpha Subunitlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchCurcuminSWATH-MSK562 CellsTyrosine kinaseK562 cellsChronic myelogenous leukemiamedicine.drug
researchProduct